Results 41 to 50 of about 9,281 (210)

Table_1_Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients.docx

, 2022
Background and objectivesCerebrospinal fluid (CSF) and interstitial fluid exchange along a brain-wide network of perivascular spaces (PVS) termed the ‘glymphatic system’.
Shu-Wei Bai (13878644), Li Xie (108913), Yi-Fan Wu (176590), Chun-Ran Xue (13878650), Mei-Chun Gao (13878641), Yang-Tai Guan (785378), Ya-Ying Song (13878647), Yong Hao (1943506), Jie Ding (73711), Xiao-Ying Yao (13878638), Ying Zhang (40767)   +10 more
core   +1 more source

High-throughput investigation of molecular and cellular biomarkers in NMOSD [PDF]

, 2020
To identify candidate biomarkers associated with neuromyelitis optica spectrum disorder (NMOSD) using high-throughput technologies that broadly assay the concentrations of serum analytes and frequencies of immune cell subsets.
Cook, Lawrence J, Zografou, Chrysoula, Smith, Terry J, Alvey, Jessica S, O'Connor, Kevin C, Sharma, Aditi, Yandamuri, Soumya S, Cotzomi, Elizabeth, Yeaman, Michael R, Ma, Anthony K, Jiang, Ruoyi   +10 more
core   +1 more source

Acute Brainstem syndrome with NMOSD and related to systemic lupus erythematosus, A Rare Case Report (PP-02) [PDF]

Neurology Letters, 2023
Introduction: Neuromyelitis optica spectrum disorders (NMOSD) are a family of syndromes, dominated by optic neuritis (ON) and myelitis, but also including brainstem syndrome. Systemic lupus erythematosus (SLE) is an autoimmune disease that may affect the
Mohammad Amin Najafi, Mohammad Amin Reza, Shirin Shams, Ali Rahmati   +3 more
doaj  

Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder

Frontiers in Immunology, 2022
ObjectiveNeuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease preferentially affects the optic nerve and the spinal cord. The first attack usually occurs in the third or fourth decade, though patients with disease onset in the ...
Yacen Hu, Yacen Hu, Qiying Sun, Qiying Sun, Fang Yi, Fang Yi, Lingyan Yao, Lingyan Yao, Yun Tian, Yun Tian, Haiyun Tang, Mengchuan Luo, Mengchuan Luo, Nina Xie, Nina Xie, Zhiqin Wang, Zhiqin Wang, Xinxin Liao, Xinxin Liao, Lin Zhou, Lin Zhou, Hongwei Xu, Hongwei Xu, Hongwei Xu, Yafang Zhou, Yafang Zhou   +25 more
doaj   +1 more source

Neuroophthalmological evaluation in primary inflammatory demyelinating diseases with special reference to optic neuritis: A prospective study

Journal of Family Medicine and Primary Care
Introduction: The involvement of ocular system especially optic neuritis (ON) is an important clinical aspect of inflammatory demyelinating disease (IDD) of the central nervous system.
Ankit Khetan, Rajesh Verma, Rajarshi Chakraborty, Ravindra Kumar Garg, Hardeep Singh Malhotra, Praveen Kumar Sharma, Neeraj Kumar, Ravi Uniyal, Shweta Pandey, Imran Rizvi   +9 more
doaj   +1 more source

Opposing Influences of Optic Neuritis and Transverse Myelitis on the Future Location of Relapses in MOG Antibody–Associated Disease

Brain and Behavior
Background Studies in MS and NMOSD have shown that relapses can frequently occur in the same location as the first attack. Factors associated with this outcome in MOGAD are unclear.
Daniel Lordelo San Martin, Marcos Baruch Portela Filho, Chiara Rocchi, Shahd Hamid, Saif Huda   +4 more
doaj   +1 more source

CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage

Journal of Neuroinflammation, 2022
Background Despite rigorous confirmation with reliable assays, some individuals showing the neuromyelitis optica spectrum disorder (NMOSD) phenotype remain negative for both aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies ...
Jae-Won Hyun, Yeseul Kim, Ki Hoon Kim, Su-Hyun Kim, Mads Nikolaj Olesen, Nasrin Asgari, Sasitorn Siritho, Friedemann Paul, Ho Jin Kim   +8 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder

Journal of Neuroinflammation, 2018
Background Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system. Although complement-dependent astrocyte damage mediated by anti-aquaporin 4 autoantibody (AQP4-Ab) is well acknowledged to be the core of ...
Kazuya Yamashita, Makoto Kinoshita, Katsuichi Miyamoto, Akiko Namba, Mikito Shimizu, Toru Koda, Tomoyuki Sugimoto, Yuki Mori, Yoshichika Yoshioka, Yuji Nakatsuji, Atsushi Kumanogoh, Susumu Kusunoki, Hideki Mochizuki, Tatsusada Okuno   +13 more
doaj   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source